Long-term follow-up of clinical trials of blood pressure–lowering medications has suggested
a continuation of event reduction after study completion. We evaluated the persistence of …

Background: Choice of antihypertensive drugs is also based on the expected burden of
adverse events associated with each class of agents, and we have recently identified …

Background: Previous meta-analyses of randomized controlled trials (RCTs) of blood
pressure (BP)-lowering treatment provided overwhelming evidence that treatment markedly …

Overviews (meta-analyses) of the major ongoing randomized trials of blood pressure
lowering drugs will be conducted to determine the effects of: first, newer versus older classes …

Abstract Short-term (4–8 weeks) placebo-controlled trials are used to evaluate new
antihypertensive drug treatment. To evaluate the consequences of such practice, a …

Background: Randomized controlled trials (RCTs) of blood pressure (BP) lowering lend
themselves to be meta-analyzed to help providing evidence-based recommendations for …

Methods: A database search between 1966 and August 2014 ide ntified 50 eligible
randomized controlled trials for 58 two-drug comparisons (247 006 patients for 1 029 768 …

Methods: A total of 55 RCTs (195 267 individuals) were suitable for drug-class meta-
analyses. Risk ratios and their 95% confidence intervals of seven fatal and nonfatal …

The last two decades witnessed the publication of a large number of clinical outcome trials
of blood pressure lowering agents in hypertensive patients or normotensive subjects with a …

Objectives In many current guidelines, blood pressure (BP)-lowering drug treatment for
primary prevention of cardiovascular disease (CVD) is based on absolute risk. However, in …